Sls Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 26-04-2024
- Paid Up Capital ₹ 2.00 M
as on 26-04-2024
- Company Age 11 Year, 7 Months
- Last Filing with ROC 31 Mar 2018
- Revenue 1025.87%
(FY 2018)
- Profit 222.38%
(FY 2018)
- Ebitda 5261.83%
(FY 2018)
- Net Worth 167.06%
(FY 2018)
- Total Assets 1764.56%
(FY 2018)
About Sls Pharmaceuticals
- CIN/LLPIN
U24232TG2013PTC087974
- Company No.
087974
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 May 2013
- Date of AGM
29 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sls Pharmaceuticals Private Limited offer?
Sls Pharmaceuticals Private Limited offers a wide range of products and services, including Pharmaceutical Medicine, Chemical Reagents & Catalysts, Ammonium Compound.
Who are the key members and board of directors at Sls Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satya Mulukutla  | Managing Director | 28-May-2013 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Tangirala Kumar | Director | 10-May-2014 | Current |
| Nudurumati Kumar | Director | 23-May-2015 | Current |
Financial Performance of Sls Pharmaceuticals.
Sls Pharmaceuticals Private Limited, for the financial year ended 2018, experienced significant growth in revenue, with a 1025.87% increase. The company also saw a substantial improvement in profitability, with a 222.38% increase in profit. The company's net worth Soared by an impressive increase of 167.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sls Pharmaceuticals?
In 2018, Sls Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Mjs Life Sciences Private LimitedActive 5 years 11 months
Satya Mulukutla and Nudurumati Kumar are mutual person
- Mjs Pharmaceuticals Private LimitedActive 5 years 11 months
Satya Mulukutla and Nudurumati Kumar are mutual person
- Sls Life Sciences Private LimitedActive 6 years 1 month
Satya Mulukutla and Nudurumati Kumar are mutual person
- Mjs Infotech Private LimitedActive 5 years 11 months
Satya Mulukutla and Nudurumati Kumar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sls Pharmaceuticals?
Unlock and access historical data on people associated with Sls Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sls Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sls Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
